作者
Sridhar V Basavaraju, Monica E Patton, Kacie Grimm, Mohammed Ata Ur Rasheed, Sandra Lester, Lisa Mills, Megan Stumpf, Brandi Freeman, Azaibi Tamin, Jennifer Harcourt, Jarad Schiffer, Vera Semenova, Han Li, Bailey Alston, Muyiwa Ategbole, Shanna Bolcen, Darbi Boulay, Peter Browning, Li Cronin, Ebenezer David, Rita Desai, Monica Epperson, Yamini Gorantla, Tao Jia, Panagiotis Maniatis, Kimberly Moss, Kristina Ortiz, So Hee Park, Palak Patel, Yunlong Qin, Evelene Steward-Clark, Heather Tatum, Andrew Vogan, Briana Zellner, Jan Drobeniuc, Matthew RP Sapiano, Fiona Havers, Carrie Reed, Susan Gerber, Natalie J Thornburg, Susan L Stramer
发表日期
2021/6/15
期刊
Clinical Infectious Diseases
卷号
72
期号
12
页码范围
e1004-e1009
出版商
Oxford University Press
简介
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in December 2019, with subsequent worldwide spread. The first US cases were identified in January 2020.
Methods
To determine if SARS-CoV-2–reactive antibodies were present in sera prior to the first identified case in the United States on 19 January 2020, residual archived samples from 7389 routine blood donations collected by the American Red Cross from 13 December 2019 to 17 January 2020 from donors resident in 9 states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at the Centers for Disease Control and Prevention for anti–SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan-Ig) enzyme …
学术搜索中的文章
SV Basavaraju, ME Patton, K Grimm, MAU Rasheed… - Clinical Infectious Diseases, 2021